UPDATE: Jefferies Starts Werewolf Therapeutics Inc. (HOWL) at Buy, 'Call of the Wild-Type IL-2'
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
'Cancer's Worst Nightmare': Street Bullish on Werewolf Therapeutics (HOWL) Amid Sustainable Growth Prospects
May 25, 2021 8:43 AM EDTAt least four Wall Street firms have started coverage on Werewolf Therapeutics (NASDAQ: HOWL) with bullish views on the company.
The company raised $120 million in its Wall Street debut in April after it ended 2020 with $93 million in the bank. In January, the company raised $72 million to further boost its balance sheet. In the IPO, Wolf sold 7.5 million shares at $16 each, a million more shares than previously communicated.
Jefferies analyst Chris Howerton starts with... More
